Ketamine Safety and Tolerability in Clinical Trials for Treatment-Resistant Depression
The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: Ketamine has demonstrated rapid antidepressant effects in patients with treatment-resistant depression (TRD); however, the safety and tolerability of ketamine in this population have not been fully described. Herein we report the largest study to date of the safety, tolerability, and acceptability of ketamine in TRD. METHOD: Data from 205 intravenous (IV) ketamine infusions (0.5 mg/kg over 40 minutes) in 97 participants with DSM-IV-defined major depressive disorder (MDD) were pooled from 3 clinical trials conducted between 2006 and 2012 at 2 academic medical centers. Safety and tolerability measures included attrition, adverse events (AEs), hemodynamic changes, and assessments of psychosis and dissociation. RESULTS: The overall antidepressant response rate, defined as a ≥ 50% improvement in Montgomery-Asberg Depression Rating Scale score, was 67% (65 of 97 participants). Four of 205 infusions (1.95%) were discontinued due to AEs. The overall attrition rate was 3.1% (3 of 97). In the first 4 hours after the infusion, the most common general AEs were drowsiness, dizziness, poor coordination, blurred vision, and feeling strange or unreal. Approximately one third of individuals experienced protocol-defined hemodynamic changes. Ketamine resulted in small but significant increases in psychotomimetic and dissociative symptoms (all P < .05). There were no cases of persistent psychotomimetic effects, adverse medical effects, or increased substance use in a subgroup of patients with available long-term follow-up information. CONCLUSIONS: In this relatively large group of patients with TRD, ketamine was safe and well tolerated. Further research investigating the safety of ketamine in severe and refractory depression is warranted. TRIAL REGISTRATION: ClinicalTrials.gov identifiers: NCT00419003, NCT00548964, and NCT00768430.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Minimal clinical research supports these findings, suggesting that risks of dependency are extremely low when ketamine is administered in a medical setting [158-160]”
From Ketamine in neuropsychiatric disorders: an update (2024) · cites this paper as [160]
In the citing paper
“Wan et al. [14] reported higher transient BP increases (peak increase of 19.6/13.4 mmHg based on 205 ketamine infusions) [14].”
From Cardiac Safety of Esketamine Nasal Spray in Treatment-Resistant Depression: Results from the Clinical Development Program (2020) · cites this paper as [14]
Citations
Cites
Clozapine for the Treatment-Resistant Schizophrenic: A Double-blind Comparison With Chlorpromazine
Kane, J. (1988) · Archives of General Psychiatry · doi:10.1001/archpsyc.1988.01800330013001 · Cited by 4,156
Antidepressant effects of ketamine in depressed patients
Berman, R. M., Cappiello, A., Anand, A., Oren, D. A., Heninger, G. R., Charney, D. S., & Krystal, J. H. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00230-9 · Cited by 3,856
Self-citationA randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Zarate, C. A., Singh, J. B., Carlson, P. J., Brutsche, N. E., Ameli, R., Luckenbaugh, D. A., Charney, D. S., & Manji, H. K. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.8.856 · Cited by 3,766
Self-citationKrystal, J. H. (1994) · Archives of General Psychiatry · doi:10.1001/archpsyc.1994.03950030035004 · Cited by 3,330
Murrough, J. W., Iosifescu, D. V., Chang, L. C., Al Jurdi, R. K., Green, C. E., Perez, A. M., Iqbal, S., Pillemer, S., Foulkes, A., Shah, A., et al. (2013) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2013.13030392 · Cited by 1,205
Self-citationDiazgranados, N., Ibrahim, L., Brutsche, N. E., Newberg, A., Kronstein, P., Khalife, S., Kammerer, W. A., Quezado, Z., Luckenbaugh, D. A., Salvadore, G., et al. (2010) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2010.90 · Cited by 963
Bremner, J. D., Krystal, J. H., Putnam, F. W., Southwick, S. M., Marmar, C., Charney, D. S., & Mazure, C. M. (1998) · Journal of Traumatic Stress · doi:10.1023/a:1024465317902 · Cited by 817
Self-citationZarate, C. A., Brutsche, N. E., Ibrahim, L., Franco-Chaves, J., Diazgranados, N., Cravchik, A., Selter, J., Marquardt, C. A., Liberty, V., & Luckenbaugh, D. A. (2012) · Biological Psychiatry · doi:10.1016/j.biopsych.2011.12.010 · Cited by 811
Murrough, J. W., Perez, A. M., Pillemer, S., Stern, J., Parides, M. K., aan het Rot, M., Collins, K. A., Mathew, S. J., Charney, D. S., & Iosifescu, D. V. (2013) · Biological Psychiatry · doi:10.1016/j.biopsych.2012.06.022 · Cited by 786
Self-citation(2001) · PubMed · Cited by 780
Cited by
Items 101–200 of 229
Ketamine, benzoate, and sarcosine for treating depression
Cheng, Y., Lin, C., & Lane, H. (2022) · Neuropharmacology · doi:10.1016/j.neuropharm.2022.109351 · Cited by 21
Cardiovascular effects of repeated subanaesthetic ketamine infusion in depression
Zhou, Y., Liu, W.-J., Wang, C., Zheng, W., Lan, X., Weng, S.-Y., & Ning, Y. (2020) · Journal of Psychopharmacology · doi:10.1177/0269881120936909 · Cited by 22
“Mild and reversible psychotomimetic and dissociative symptoms have been reported in a subgroup of patients with depression (Wan et al., 2015); however, no study to date has investigated whether these symptoms are related to the cardiovascular effects of ketamine.”
BackgroundResultInfluentialThe effect of physical activity on anhedonia in individuals with depressive symptoms
Sun, C., Wang, Y., Fang, Y., He, Y., Wang, X., So, B. C. L., Shum, D., & Yan, C. (2021) · PsyCh Journal · doi:10.1002/pchj.485 · Cited by 20
Characteristics and circumstances of death related to the self‐administration of ketamine
Darke, S. G., Duflou, J. A., Farrell, M., Peacock, A., & Lappin, J. (2020) · Addiction · doi:10.1111/add.15154 · Cited by 22
Risk of Renal Function Decline in Patients with Ketamine-Associated Uropathy
Ou, S., Wu, L.-Y., Chen, H.-Y., Huang, C., Hsu, C., Chen, C., Chou, K.-J., Fang, H.-C., & Lee, P. (2020) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph17197260 · Cited by 17
“In addition, it has been adopted as an agent in the treatment of major depression, treatment-resistant depression, and bipolar affective disorder [1,2].”
BackgroundPai, S. M., & Gries, J. (2021) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.1983 · Cited by 16
Metabolic Risk Factors and Cardiovascular Safety in Ketamine Use for Treatment Resistant Depression
Szarmach, J., Cubała, W. J., Włodarczyk, A., & Gałuszko‐Węgielnik, M. (2020) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s273287 · Cited by 18
Craving and addictive potential of esketamine as side effects?
Orsolini, L., Salvi, V., & Volpe, U. (2022) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2022.2071422 · Cited by 18
“All side effects resolved quickly post-infusion, and no significant medical effects or increased substance use was observed [29,39].”
BackgroundNovel uses of ketamine in the emergency department
Corwell, B. N., Motov, S. M., Davis, N. L., & Kim, H. (2022) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2022.2100883 · Cited by 16
Driver, C., Jackson, T., Lagopoulos, J., & Hermens, D. F. (2022) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2022.110609 · Cited by 18
Yip, R., Swainson, J., Khullar, A., McIntyre, R. S., & Skoblenick, K. J. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.1017504 · Cited by 20
“4 mmHg with blood pressures returning to baseline at 60–70min after infusion (33).”
BackgroundRepeated subcutaneous racemic ketamine in treatment-resistant depression: case series
Tham, J. C. W., Do, A., Fridfinnson, J. A., Rafizadeh, R., Siu, J. T. P., Budd, G. P., & Lam, R. W. M. (2022) · International Clinical Psychopharmacology · doi:10.1097/yic.0000000000000409 · Cited by 15
Wang, S., Tang, S., Huang, J., & Chen, H. (2022) · General Psychiatry · doi:10.1136/gpsych-2022-100922 · Cited by 15
“20 36 AnTAgonIsTs of group II meTAboTropIC gluTAmATe reCepTors (mglurs) Glutamate receptors mediate excitatory synaptic transmission in the central nervous system and are divided into two subtypes: ionotropic receptors and mGluRs.”
BackgroundLee, C., Lee, J. H., Lee, G., Lee, H., Shicheng, Z., & Hwang, J. (2018) · Psychopharmacology · doi:10.1007/s00213-018-4939-z · Cited by 14
Gonzalez, S., Vasavada, M. M., Njau, S. N., Sahib, A. K., Espinoza, R. T., Narr, K. L., & Leaver, A. M. (2020) · Neurology Psychiatry and Brain Research · doi:10.1016/j.npbr.2020.08.006 · Cited by 14
Garel, N., Greenway, K. T., Dinh-Williams, L.-A. L., Thibault-Levesque, J., Jutras-Aswad, D., Turecki, G., Rej, S., & Richard-Devantoy, S. (2023) · Neuropsychopharmacology · doi:10.1038/s41386-023-01689-y · Cited by 13
“We set a priori continuation rules as described in the statistical analysis section.”
MethodDecazes, E., Rigal, O., & Clatot, F. (2023) · Palliative & Supportive Care · doi:10.1017/s1478951523000317 · Cited by 13
“It should be noted that the 1-mg/kg dose is higher than that typically used in psychiatric studies even though doses of 1 mg/kg have been used (Wan et al. 2015).”
Krupp, K. T., Yaeger, J. D. W., Ledesma, L. J., Withanage, M. H. H., Gale, J., Howe, C. B., Allen, T. J., Sathyanesan, M., Newton, S. S., & Summers, C. H. (2024) · Neuropharmacology · doi:10.1016/j.neuropharm.2024.109949 · Cited by 13
“…of treatment has recently been broadened by current research on ketamine (De Gregorio et al., 2021; Krystal et al., 2019; Phillips et al., 2019; Wan et al., 2015), orexin drugs (Staton et al., 2018; Yaeger et al., 2020, 2022a, 2022b) and psychedelics (Carhart-Harris et al., 2018;…”
Ketamine treatment for depression: A model of care
Bayes, A. J., Dong, V., Martin, D. M., Alonzo, A., Kabourakis, M., & Loo, C. K. A. (2021) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/00048674211039166 · Cited by 12
“As there are no significant changes in oxygen saturation in patients administered ketamine (Wan et al., 2015), we do not routinely monitor oxygen saturation across a treatment episode unless there are reasons for concern (e.g. patient is very sedated, has sleep apnoea or a comorbid pulmonary…”
BackgroundInfluentialRyan, K., & Hosanagar, A. (2023) · Current Psychiatry Reports · doi:10.1007/s11920-023-01432-w · Cited by 11
Bloomfield, A., Chan, N. W., Fryml, L. D., Horace, R. W., & Pyati, S. (2023) · Current Pain and Headache Reports · doi:10.1007/s11916-023-01150-1 · Cited by 16
Hovda, N., Gerrish, W. G., Frizzell, W., & Shackelford, R. (2023) · Journal of Affective Disorders · doi:10.1016/j.jad.2023.10.120 · Cited by 15
Echegaray, M. V. F., Mello, R. P., Magnavita, G. M., Leal, G. C.-G., Correia‐Melo, F. S., Jesus‐Nunes, A. P., Vieira, F., Bandeira, I. D., Caliman‐Fontes, A. T., Telles, M., et al. (2023) · Trends in Psychiatry and Psychotherapy · doi:10.47626/2237-6089-2022-0593 · Cited by 14
“7-12 Recently, the Canadian Network for Mood and Anxiety Treatments (CANMAT) guideline included a single infusion of racemic ketamine as having level 1 evidence for treatment of TRD, 13 and the Food and Drug Administration (FDA) also approved intranasal esketamine for TRD. 14 Identifying predictors…”
The possible place for psychedelics in pharmacotherapy of mental disorders
Wojtas, A. (2023) · Pharmacological Reports · doi:10.1007/s43440-023-00550-9 · Cited by 14
“Nausea is another commonly reported side effect, seen in approximately 30–40% of patients [66].”
BackgroundMukhaizeem, S. A., Nasa, A., Waldron, D., McDaid, A., Gorman, P., Featherstone, M., Barry, M., Murphy, P. M., Gallagher, H., Nair, S., et al. (2023) · Frontiers in Pain Research · doi:10.3389/fpain.2023.1268985 · Cited by 12
“Both the anaesthetic and analgesic properties of ketamine are primarily due to NMDAR antagonism (19).”
BackgroundPerioperative ketamine for acute analgesia and beyond.
Porter, S. B. (2019) · PubMed · doi:10.2478/rjaic-2019-0010 · Cited by 14
Clinical Outcome of Augmentation Enterocystoplasty for Patients with Ketamine-induced Cystitis
Kuo, H. (2017) · Pain Physician · doi:10.36076/ppj.2017.e436 · Cited by 11
Effects of chronic bryostatin-1 on treatment-resistant depression in rats
Alkon, D. L., Hongpaisan, J., & Sun, M. (2017) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2017.05.001 · Cited by 12
“The potential problems with these antagonists as antidepressants include the facts that their intended selectivity for targeting negative memory is only partial at most and that the efficacy of ketamine tends to wear off in time, in addition to other adverse effects (Wan et al., 2015).”
BackgroundKetamine for Treatment-Resistant Depression: a New Advocate
Pérez‐Esparza, R. (2018) · Revista de investigaci�n Cl�nica · doi:10.24875/ric.18002501 · Cited by 14
Bottemanne, H., Claret, A., & Fossati, P. (2020) · L Encéphale · doi:10.1016/j.encep.2020.08.006 · Cited by 15
Souza‐Marques, B., Telles, M., Leal, G. C.-G., Faria-Guimarães, D., Correia‐Melo, F. S., Jesus‐Nunes, A. P., Vieira, F., Souza, L. S., Lins-Silva, D. H., Mello, R. P., et al. (2022) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000001571 · Cited by 12
Du, E., McAllister, P., Venna, V. R., & Xiao, L. (2016) · Journal of Cellular Biochemistry · doi:10.1002/jcb.25772 · Cited by 10
“In addition, recent studies have shown that administration of sub-anesthetic doses of ketamine can have fastacting antidepressant effects on both treatment-naive and -resistant depression patients [Murrough et al., 2013; Fond et al., 2014; Wan et al., 2014; McGirr et al., 2015].”
Sakopoulos, S., & Todman, M. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26146673 · Cited by 12
“Potential side effects may include dizziness, dissociation, nausea, sedation, and changes in blood pressure and heart rate [21,35,36,55].”
Su, T. (2019) · Frontiers in Neuroscience · doi:10.3389/fnins.2019.00761 · Cited by 10
Gold, M. S., Cadet, J. L., Baron, D. A., Badgaiyan, R. D., & Blum, K. (2020) · Journal of Systems and Integrative Neuroscience · doi:10.15761/jsin.1000227 · Cited by 13
Włodarczyk, A., Cubała, W. J., Gałuszko‐Węgielnik, M., & Szarmach, J. (2021) · Therapeutic Advances in Psychopharmacology · doi:10.1177/20451253211011021 · Cited by 9
Lee, W., Sheehan, C., Chye, R., Chang, S., Bayes, A. J., Loo, C. K. A., Draper, B., Agar, M. R., & Currow, D. C. (2023) · PLoS ONE · doi:10.1371/journal.pone.0290876 · Cited by 11
Ketamine for depression: a potential role in requests for Medical Aid in Dying?
Garel, N., Nazon, M., Naghi, K., Willis, E., Looper, K. J., Rej, S., & Greenway, K. T. (2023) · International Clinical Psychopharmacology · doi:10.1097/yic.0000000000000462 · Cited by 8
“Multiple clinical trials have found high tolerability and acceptability of ketamine (Wan et al., 2015), particularly relative to electroconvulsive therapy.”
BackgroundLandrigan, J., Shawaf, F., Dwyer, Z., Abizaid, A. B., & Hayley, S. P. (2016) · Neuroscience Letters · doi:10.1016/j.neulet.2016.08.015 · Cited by 8
Sobreiro, M. D. F. M., Silveira, P. S. P., Cavenaghi, V. B., da Costa, L. P., de Souza, B. P. F., Takahashi, R. E. S., Starek, R. V. M., Siqueira, J. D. O., & Fráguas, R. (2025) · Pharmaceuticals · doi:10.3390/ph18020173 · Cited by 7
“Both the racemic presentation of ketamine [12] and its S-enantiomer, esketamine, have demonstrated robust efficacy in treating TRD [13].”
Herpers, J., Maximets, N., van Dongen, N. N. N., Zijlmans, J., & Vermetten, E. H. G. J. M. (2024) · European Journal of Psychotraumatology · doi:10.1080/20008066.2024.2378651 · Cited by 9
“Ketamine, although rapidly effective, carries risks of dissociation, potential for abuse, and long-term cognitive effects (Wan et al., 2015).”
BackgroundZhang, M. W., & Ho, R. (2016) · Ethics & Behavior · doi:10.1080/10508422.2016.1189333 · Cited by 8
“Third, most researchers described ketamine as nonaddictive at a subanesthetic dose and addictive only at higher doses (Wan et al., 2015).”
BackgroundInfluentialPre-treatment Pain Symptoms Influence Antidepressant Response to Ketamine in Depressive Patients
Lan, X., Zhou, Y., Wang, C., Li, W., Zhang, F., Liu, H., Fu, L., Wu, K., McIntyre, R. S., & Ning, Y. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.793677 · Cited by 11
“In addition, a longer-term follow-up study (range, 8 months to 6 years) that carried an open-label ketamine infusion three times weekly over a 12-day period showed that no persistent physical symptoms or increased substance use were found in participants, suggesting longer-term safety of ketamine treatment (46).”
BackgroundLiang, X., Yang, X. N., Liang, S., Zhang, Y., Ding, Z., Guo, Q., & Huang, C. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11144129 · Cited by 7
“Thus, we could not distinguish whether the patients’ headaches, nausea, and vomiting were caused by low cranial pressure or the psychiatric-related side effects of ketamine [41,42].”
BackgroundMaltbie, E. A., Gopinath, K., & Howell, L. L. (2019) · Psychopharmacology · doi:10.1007/s00213-019-05204-4 · Cited by 7
The Basic and Clinical Pharmacology of Ketamine
Fourcade, E. W., & Lapidus, K. A. B. (2016) · Springer eBooks · doi:10.1007/978-3-319-42925-0_2 · Cited by 9
Early optimized pharmacological treatment in patients with depression and chronic pain
Oluboka, O. J., Katzman, M. A., Habert, J., Khullar, A., Oakander, M. A., McIntosh, D., McIntyre, R. S., Soares, C. N., Lam, R. W. M., Klassen, L. J., et al. (2022) · CNS Spectrums · doi:10.1017/s1092852922000128 · Cited by 10
Blood pressure changes during ketamine infusion for the treatment of depression
Ansari, M., Pittman, B. P., Tylee, D. S., Ostroff, R. B., Wilkinson, S. T., & Nikayin, S. (2024) · General Hospital Psychiatry · doi:10.1016/j.genhosppsych.2024.07.001 · Cited by 8
Ketamine in the Treatment of Major Depressive Disorder
Luu, B., Rice, E. I., & Goldin, P. R. (2019) · The Journal for Nurse Practitioners · doi:10.1016/j.nurpra.2019.07.016 · Cited by 7
The Unmet Needs for Major Depressive Disorder
McIntyre, R. S., & Gill, H. (2020) · Springer eBooks · doi:10.1007/978-3-030-42637-8_3 · Cited by 8
Gallagher, B., Foley, M., Slattery, C. M., Gusciute, G., Shanahan, E., & McLoughlin, D. M. (2020) · HRB Open Research · doi:10.12688/hrbopenres.13182.1 · Cited by 10
Lee, W., Sheehan, C., Chye, R., Chang, S., Loo, C. K. A., Draper, B., Agar, M. R., & Currow, D. C. (2021) · BMJ Open · doi:10.1136/bmjopen-2021-052312 · Cited by 8
Tashakkori, M., Ford, A. H., Dragović, M., Gabriel, L., & Waters, F. (2020) · Australasian Psychiatry · doi:10.1177/1039856220961642 · Cited by 6
Xiao, X., Bentzley, B. S., Cole, E. J., Tischler, C., Stimpson, K. H., Duvio, D., Bishop, J. H., DeSouza, D. D., Schatzberg, A. F., Keller, C. J., et al. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/672154 · Cited by 7
“Ketamine induces brief remission rapidly but only in a third of patients (12, 13) and with significant off-target effects (14, 15).”
BackgroundSubanesthetic Ketamine Suppresses Locus Coeruleus–Mediated Alertness Effects: A 7T fMRI Study
Liebe, T., Danyeli, L. V., Şen, Z. D., Li, M., Kaufmann, J., & Walter, M. (2024) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyae022 · Cited by 5
“…antidepressant, and numerous studies show promising effects in the treatment of major depressive disorder (MDD), which are corroborated by meta-analyses ( Berman et al., 2000a; Zarate et al., 2006; Caddy et al., 2014; Fond and Boyer, 2014; McGirr et al., 2015; Wan et al., 2015; Bahji et al., 2020).”
Lowe, D. J. E., Müller, D. J., & George, T. P. (2020) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026620666200423094423 · Cited by 5
Can Quetiapine Prolong the Antidepressant Effect of Ketamine? A 5-Year Follow-up Study
Amiaz, R., Saporta, R., Noy, A., Berkenstadt, H., & Weiser, M. (2021) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000001489 · Cited by 4
Gillespie, C. F., Szabo, S. T., & Nemeroff, C. B. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-813866-3.00036-9 · Cited by 7
Higher glutamatergic activity in the medial prefrontal cortex in chronic ketamine users
Wu, Q., Tang, J., Qi, C., Xie, A., Liu, J., O’Neill, J., Liu, T., Hao, W., & Liao, Y. (2022) · Journal of Psychiatry and Neuroscience · doi:10.1503/jpn.210179 · Cited by 4
“Long-term exposure to ketamine led to dysfunction of glutamate homeostasis in the mPFC of rats, with reduced expression of NMDA receptors and metabotropic glutamate receptor 5, 63 resembling findings in schizophrenia.”
Forouzanfar, F., Ahmadzadeh, A. M., Pourbagher‐Shahri, A. M., & Gorji, A. (2025) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2025.177690 · Cited by 4
Maropitant ou cetamina para o controle da dor em cadelas submetidas à ovariohisterectomia
Favaretto, A. F., Mastrocinque, S., Macedo, J. D. S., & Rossetti, R. B. (2022) · PubVet · doi:10.31533/pubvet.v16n05a1111.1-8 · Cited by 4
Finnegan, M., Ryan, K. M., Shanahan, E., Harkin, A., Daly, L., & McLoughlin, D. M. (2016) · Pilot and Feasibility Studies · doi:10.1186/s40814-016-0080-0 · Cited by 5
“BDNF mediates synaptic plasticity and is implicated in mechanisms of antidepressants and ECT [18].”
BackgroundKetamine: Its Safety, Tolerability, and Impact on Neurocognition
RYBAKOWSKI, J. K., Permoda‐Osip, A., & Bartkowska‐Śniatkowska, A. (2016) · Springer eBooks · doi:10.1007/978-3-319-42925-0_5 · Cited by 4
Pain and its Management in Severe Acute Pancreatitis
Jiang, Z., Long, Y., & Wu, G. (2022) · Journal of Translational Critical Care Medicine · doi:10.4103/jtccm-d-21-00026 · Cited by 7
Schuman, H. D. M., Barkova, S., Mina, R., Deleemans, J. M., Nguyen, T. T.-T. N., & Carlson, L. E. (2025) · Integrative Cancer Therapies · doi:10.1177/15347354251370982 · Cited by 4
Campolina, A. G., & de Oliveira, M. A. T. (2025) · Healthcare · doi:10.3390/healthcare13212714 · Cited by 5
Lan, X., Liu, H., Wang, C., Li, W., Zhang, F., Hu, Z., Chen, X., You, Z., Ning, Y., & Zhou, Y. (2024) · Biology of Sex Differences · doi:10.1186/s13293-024-00587-2 · Cited by 3
“Although ketamine showed acceptable short-term side effects such as headache, nausea, psy-chotomimetic and dissociative symptoms, it might have the potential risks of abuse and neurotoxicity [20].”
BackgroundKetamine-Associated Uropathy: From Presentation to Management
Yee, C., Ma, W. K., Ng, C., & Chu, S.-K. P. (2016) · Current Bladder Dysfunction Reports · doi:10.1007/s11884-016-0380-5 · Cited by 4
Kellner, C. H. (2018) · Cambridge University Press eBooks · doi:10.1017/9781108242028.004 · Cited by 4
Sandström, K., Kampman, O., & Asellus, P. (2024) · Acta Neuropsychiatrica · doi:10.1017/neu.2024.18 · Cited by 3
“(Wan et al ., 2015; Corriger and Pickering, 2019; Jelen and Stone, 2021).”
Ketamine in treatment-resistant depression
Berthold‐Losleben, M., Autran, I., Folstad, R. L. S., Römer, B., Kvam, T.-M., van de Vooren, I.-T. J., Stewart, L. H., Clausen, I., & Andreassen, O. A. (2025) · Tidsskrift for Den norske legeforening · doi:10.4045/tidsskr.25.0045 · Cited by 3
Progress, potential and pitfalls of ketamine as a treatment for depression
Orsini, D. K., Luch, S. D. D., Lovell, G. F. M., & Rosenblat, J. D. (2026) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2026.2637587 · Cited by 2
“Now with longer term studies, extensive data has been accumulated to support the safety and tolerability of both acute course and maintenance, long-term repeated treatments [29–31].”
Evaluating the abuse liability of ketamine in the treatment of mood disorders: A systematic review
Vasudeva, S., Lovell, G. F. M., Wong, S., Le, G. H., Orsini, D. K., Luch, S. D. D., McIntyre, R. S., & Rosenblat, J. D. (2026) · Journal of Psychopharmacology · doi:10.1177/02698811261453814 · Cited by 2
The Modulation of Glutamatergic Signaling as a Potential Therapeutic Strategy for Major Depression
Molero, P., Aubá, E., Unceta, M. D. M., & Pedreño, F. O. S. (2022) · Springer eBooks · doi:10.1007/978-3-030-87480-3_11 · Cited by 2
The Role of Ketamine in Treatment-resistant Depression: A Narrative Review
Reddy, A., Patel, S. G., Barik, A. K., Thappa, P., Jangra, K., Kaur, K., Chauhan, R., & Luthra, A. (2024) · Journal of Exploratory Research in Pharmacology · doi:10.14218/jerp.2024.00003 · Cited by 4
Lord, B., Simavorian, S., Fraser, I. C., Welty, N., Wyatt, R. M., Pritchard, R. A., Fletcher, L., van der Linde, H. J., Bounkhoun, D., Libiger, O., et al. (2025) · British Journal of Pharmacology · doi:10.1111/bph.70069 · Cited by 2
“NMDA receptor dysfunction is implicated in psychiatric disorders, and while antagonists of these receptors have shown efficacy as RAADs, they can cause haemodynamic effects and dissociation (Wan et al., 2015).”
Glutamate NMDA receptor modulators for the treatment of depression: trials and tribulations
Murrough, J. W. (2015) · Psychopharmacology · doi:10.1007/s00213-015-3888-z · Cited by 3
“The total number of subjects studied in RCTs of ketamine in depression is less than 200 and no studies have examined the effects of ketamine over a longer time interval than a few weeks (Wan et al. 2014).”
Self-citationFischer, M., & Abd-Elsayed, A. A. (2019) · Springer eBooks · doi:10.1007/978-3-030-17478-1_2 · Cited by 2
Li, C., Su, T., Chen, M., & Lin, W.-C. (2020) · Taiwanese Journal of Psychiatry · doi:10.4103/tpsy.tpsy_19_20 · Cited by 2
“found that the overall antidepressant response rate, defined as a ≥ 50% improvement in the Montgomery–Åsberg Depression Rating Scale (MADRS), is 67% [6].”
BackgroundKetamine: Safe and Effective Treatment for Severe Depression
Koss, T. B. (2021) · Journal of the American Psychiatric Nurses Association · doi:10.1177/10783903211033023 · Cited by 2
“Although many have reservations about the use of ketamine and its potential for abuse, a retrospective analysis of healthy participants who received subanesthetic IV ketamine in a research setting found no persistent adverse mental status events, no residual medical sequelae, and no long-term increased risk for ketami…”
BackgroundAhuja, S., Brendle, M., Smart, L., Moore, C., Thielking, P. D., & Robison, R. J. (2022) · Research Square · doi:10.21203/rs.3.rs-1331173/v1 · Cited by 2
Ketamine and Its Pharmacologic Profile in Psychiatric Disorders
Dugar, A., Ettensohn, M. F., & Levine, S. P. (2018) · Psychiatric Annals · doi:10.3928/00485713-20180314-01 · Cited by 1
Lee, Y., Arndt, S. V., Joji, C., Fleischer, H., Shelley, M., Liu, C., & Chang, Y. (2025) · International Journal of Mental Health and Addiction · doi:10.1007/s11469-025-01506-1 · Cited by 1
“However, research on the safety and tolerability of ketamine is limited and requires careful consideration (Wan et al., 2015).”
Zhang, Y., Tan, W., Song, X., Geng, Q.-B.-H., Yuan, P., Chen, G., & Zhao, L. (2025) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2025.118138 · Cited by 1
Strous, J. F. M., Roelandt, G. H. J., van Dalfsen, J. H., Kamphuis, J., Marijnissen, R. M., & Schoevers, R. A. (2025) · International Journal of Methods in Psychiatric Research · doi:10.1002/mpr.70044 · Cited by 1
“Therefore, a dose of 75 mg IN ketamine is considered safe and potentially effective (Wan et al. 2015; Patil and Anitescu 2012).”
Courtes, A. C., Myers, B., Daly, N., Jones, G., Soares, J. C., Zarate, C. A., & Machado‐Vieira, R. (2026) · General Hospital Psychiatry · doi:10.1016/j.genhosppsych.2026.02.011 · Cited by 1
Eizaguirre, N. O., Madariaga, S. B., Osa, L., Maza, A. M., Catalán, A., Rementeria, L. L., Cosgaya, A. D., Rementería, G. P., & Torres, M. Á. G. (2015) · Psiquiatría Biológica · doi:10.1016/j.psiq.2015.11.003 · Cited by 1
Nakatsuka, D., Suwa, T., Deguchi, Y., Fujita, Y., Tashima, R., Ohnami, S., Kawashima, H., Oishi, N., Ogawa, K., Yamakawa, H., et al. (2025) · Translational Psychiatry · doi:10.1038/s41398-025-03284-9 · Cited by 2
Schoretsanitis, G., & Hasler, G. (2015) · Swiss Medical Forum ‒ Schweizerisches Medizin-Forum · doi:10.4414/smf.2015.02420 · Cited by 1
Chen, M., & Su, T. (2020) · Springer eBooks · doi:10.1007/978-981-15-2902-3_11 · Cited by 2
Ketamina eta esketaminaren erabilera depresioerresistentea tratatzeko: etorkizunerako erronkak
Elexpe, A., Bruzos-Cidón, C., Cabrera, M., Barreda‐Gómez, G., & Torrecilla, M. (2020) · EKAIA Euskal Herriko Unibertsitateko Zientzi eta Teknologi Aldizkaria · doi:10.1387/ekaia.21862
GeoComputation and Spatial Modelling for Decision-Making
Bhunia, G. S., & Shit, P. K. (2021) · Springer geography · doi:10.1007/978-3-030-71198-6_7 · Cited by 1
Ketamine and Other Glutamate Receptor Antagonists As Fast-Actin
Chen, M., Su, T., & Tsai, S. (2022) · Neuromethods · doi:10.1007/978-1-0716-2083-0_19 · Cited by 1
Is Ketamine the New Wonder Drug for Treating Suicide?
Boilini, H., Baldwin, M., & Lamvu, G. (2017) · Europe PMC (PubMed Central) · Cited by 1
Ketamine in Psychiatric Disorders
Danyeli, L. V., Götting, F. N., Şen, Z. D., Li, M., & Walter, M. (2022) · Springer eBooks · doi:10.1007/978-3-030-62059-2_420 · Cited by 1
Cardiovascular and Metabolic Comorbidities as the Factors for Adverse Events With Ketamine
Sadko, K. G., & Jakuszkowiak‐Wojten, K. (2023) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000001698 · Cited by 1
Kétamine comme option thérapeutique
Schoretsanitis, G., & Hasler, G. (2015) · Forum Médical Suisse ‒ Swiss Medical Forum · doi:10.4414/fms.2015.02420
Ketamine for Psychiatric Disorders
McShane, R. H. (2019) · Cambridge University Press eBooks · doi:10.1017/9781911623175.017
Ketamine – a prototype of rapidly acting antidepressant drugs
Zawilska, J. B., & Kacprzak, Ł. (2019) · Farmacja Polska · doi:10.32383/farmpol/116256
How to implement a ketamine clinic
Chandrasena, R. D., Fairbairn, J., Kang, M. J. Y., & Vázquez, G. H. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-821033-8.00006-x
Metadata
- Authors
- Wan, L.-B., Levitch, C. F., Perez, A. M., Brallier, J. W., Iosifescu, D. V., Chang, L. C., Foulkes, A., Mathew, S. J., Charney, D. S., & Murrough, J. W.
- ORCID
- Venue
- The Journal of Clinical Psychiatry
- Publisher
- Physicians Postgraduate Press, Inc
- Published
- 2014-09-02
- Volume
- 76
- Issue
- 03
- Pages
- 247-252
- ISSN
- 0160-6689 (ISSN-L)
- OpenAlex
- W2059761623
- Cited by
- 231
- References
- 34
- Citations by year
- 2026: 6 · 2025: 16 · 2024: 15 · 2023: 14 · 2022: 36 · 2021: 21 · 2020: 36 · 2019: 18 · 2018: 15 · 2017: 14 · 2016: 23 · 2015: 15 · 2014: 1
- FWCI
- 12.84
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (UL1TR000067)
- National Institute of Mental Health (R01MH081870, K23MH094707)
- National Center for Advancing Translational Sciences
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Medicine › Psychiatry and Mental health › Electroconvulsive Therapy Studies
- Life Sciences › Neuroscience › Neurology › Transcranial Magnetic Stimulation Studies
- Keywords
- ketamine, treatment-resistant depression, major depressive disorder, drug safety, tolerability, adverse events, psychotomimetic effects, dissociation, hemodynamic changes, antidepressant response, attrition, intravenous infusion
- MeSH terms
- Adult, Clinical Trials as Topic, Major Depressive Disorder, Female, Humans, Infusions, Intravenous, Ketamine, Male, Middle Aged, Treatment Outcome, Excitatory Amino Acid Antagonists, Depressive Disorder, Treatment-Resistant
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.